InsidersTradesSigma
한올바이오파마 Stock: price and management transactions · South Korea · DART (FSS)
Follow the 한올바이오파마 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 한올바이오파마 has published 6 insider filings. Market capitalisation: €2,311.5bn. The latest transaction was reported on 2 July 2026 (Mixed). Among the most active insiders: 국민연금공단. The full history is accessible without an account.
6
Insider Decl.
n/a
Thresholds
€19m
4 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,759 of 28,169 companies
35.7
score / 100
Value33
Quality38
FCF yld-0.6%
Earn yld-0.2%
EV/EBITDA·
ROE-3.2%
Gross mgn52%
Net mgn-3.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2026
Declarations6 total
6 of 6 declarations
About 한올바이오파마
Hanall Biopharma is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and ophthalmic disorders. It is listed on the XKRX market.